ReviewMolecular and clinical oncology2025
Recent research advances in interleukin, microRNA and neuroendocrine tumor biomarkers (Review).
Review in Molecular and clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The incidence of neuroendocrine tumors (NETs) has been increasing in recent years and most cases are not easily detected in the early stages. The diagnostic modalities used for NETs are currently limited due to the small number of individuals with this type of disease. It is clear that patients exhibit chronic inflammation in the early stages, which leads to corresponding changes in inflammatory factors and in the tumor microenvironment. Among the numerous inflammatory factors, the interleukin (IL)-6 family has a clear association with tumor development and serves a role in most NETs. In addition, the IL-6 family, through various signaling pathways, can influence tumor progression. IL-6 is also involved in the upregulation and suppression of novel biomarkers of NETs. In terms of diagnosis, the specific elevation of inflammatory factors and the alterations in non-coding RNAs for different NETs is of great importance for the early differentiation of tumor types.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.